DUAL- VERSUS MONO-ANTIPLATELET THERAPY IN PATIENTS UNDERGOING TAVR: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES

Background Current guidelines recommend dual-antiplatelet strategy (DAPT) following transcatheter aortic valve replacement (TAVR), however some studies have suggested that mono-antiplatelet strategy (MAPT) may be equally efficacious with an improved safety profile. In patients undergoing TAVR, DAPT...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2018-03, Vol.71 (11), p.A1284-A1284
Main Authors: Halabi, Shadi Al, Newman, Joshua, Farkouh, Michael E., Fortuin, David, Leya, Ferdinand, Sweeney, John, Webb, John, Lopez, John, Steen, Lowell, Lewis, Bruce, Darki, Amir, Mathew, Verghese
Format: Article
Language:English
Subjects:
Bleeding
Clinical trials
Health risk assessment
Mortality
Myocardial infarction
Observational studies
Stroke
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Current guidelines recommend dual-antiplatelet strategy (DAPT) following transcatheter aortic valve replacement (TAVR), however some studies have suggested that mono-antiplatelet strategy (MAPT) may be equally efficacious with an improved safety profile. In patients undergoing TAVR, DAPT use was associated with increased 30 day risk of the primary endpoint of death, myocardial infarction, stroke or TIA, and major or life threatening bleeding (RR 2.11 95% CI: 1.39, 3.21; p
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(18)31825-4